MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

0.5423 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational... 
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
From Century Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story